ArticleScientific reports2026
Reverse vaccinology-based design of a universal multiepitope vaccine against chikungunya virus: Phylogenetic and immunoinformatics approaches.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) infection is a re-emerging arboviral disease in tropical and subtropical regions. In addition to acute febrile syndrome, CHIKV infection may lead to chronic articular manifestations that significantly affect a long-term quality of life. This study aimed to design a universal vaccine candidate covering all circulating genotypes of CHIKV based on conserved multiepitope platform. We employed a large scale phylogenetic and immunoinformatic approach to identify conserved regions of the open reading frames (ORF2) region encoding viral structural proteins. This study ultimately identified 10 high-quality epitopes: 6 MHC-I, 1 MHC-II, and 3 B cell epitopes. The selected epitopes span multiple viral domains, including C, E1, E2, and E3, with high immunogenicity (VaxiJen ≥ 66%), non-toxic, and non-allergenic properties. These selected epitopes were utilized to design multiepitope vaccine constructs (MEV-CHIKV) linked with various linkers in combination with adjuvants (human β-defensin 3) to enhance the immune responses. Structural validation analysis showed high quality and stability of the vaccine construct. Based on molecular docking analysis, the designed vaccine has high binding affinities with the active site of TLR3. In silico immune simulation showed induction of robust adaptive immune responses, characterized by the activation and expansion of B and T cell populations. Codon optimization and rare codon analysis revealed a potentially high expression in bacterial system. Thus, the vaccine cadidate is anticipated to effectively and simultaneously induce robust cellular and humoral immune responses. In addition, it should retain its high protection upon emergence of novel mutations within the CHIKV genome. Since our study is merely in silico-based analysis, further in vitro and in vivo experimental validation to demonstrate the immunogenic properties of the vaccine candidate are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.